Periods | Baseline | L-NMMA | Post infusion | p (GLM-within) | ||
---|---|---|---|---|---|---|
0-90 min | 90-120 min | 120-150 min | 150-180 min | 180-210 min | ||
p-sodium (mmol/l) | ||||||
Placebo | 140 ± 2 | 139 ± 1 | 139 ± 2** | 139. ± 2 | 138 ± 2** | 0.272 |
Tolvaptan | 143 ± 2 | 143 ± 2 | 141 ± 3** | 141 ± 2 | 141 ± 2* | |
P (Wilcoxon’s signed rank test) | 0.001 | 0.001 | 0.002 | 0.001 | 0.001 |  |
p- osm (mosm/kg) | ||||||
Placebo | 285 ± 3 | 285 ± 4 | 283 ± 4** | 284 ± 4** | 283 ± 4*** | 0.352 |
Tolvaptan | 291 ± 3 | 291 ± 3 | 291 ± 3 | 291 ± 3 | 290 ± 3 | |
p (GLM between) <0.0001 | ||||||
p (paired t-test) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | Â |
p-potassium (mmol/l) | ||||||
Placebo | 3.8 ± 0.2 | 3.8 ± 0.3 | 3.9 ± 0.3 | 3.9 ± 0.2 | 3.8 ± 0.1 | 0.325 |
Tolvaptan | 3.9 ± 0.2 | 3.9 ± 0.2 | 4.0 ± 0.2 | 4.0 ± 0.1 | 4.0 ± 0.1 | |
p (Wilcoxon’s signed rank test) | 0.028 | 0.117 | 0.272 | 0.929 | 0.430 |  |